Horizon Therapeutics Plc

Horizon Therapeutics Plc

HZNP - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$26.6B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Horizon Therapeutics PlcHorizon Therapeutics Plc51-8%7.80.5
$275.01

Current Fair Value

136.5% upside

Undervalued by 136.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$26.60 Billion
Enterprise Value$26.70 Billion
Earnings per Share$2.28
Beta1.01
Outstanding Shares228,743,143

Return

Return on Equity8.25%ROE
Return on Assets4.71%
Return on Invested Capital6.38%

Valuation & Multiples

P/E Ratio51.01P/E Ratio
PEG47.06PEG
Price to Sales7.75Price to Sales
Price to Book Ratio5.06Price to Book Ratio
Enterprise Value to Revenue7.33
Enterprise Value to EBIT49.94
Enterprise Value to Net Income60
Total Debt to Enterprise0.1
Debt to Equity0.48Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Horizon Therapeutics Plc

Horizon Therapeutics Plc Insider Information FAQ

In the latest 13F quarter on Stockcircle, 12 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.